Viking Psychiatry & Wellness

05/26/2026

Please feel free to join us for this amazing Mental Health Resource Fair. We are proud to be part of the resources available for Warsaw and the surrounding communities. CARES

05/07/2026

It was great, demonstrating this amazing option and improving incontinence, sexual health, and beyond. So thankful we are offering treatments that can make a significant impact on our clients quality of life.

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry & Wellness, as he highlights...

05/07/2026

Today, we want to take a moment to recognize Chris Griebel, RN, our Interventional Clinical Nurse at Viking Psychiatry & Wellness.

Chris brings an extraordinary background in psychiatric nursing, including 35 years at Parkview Behavioral Health, primarily in Youth Services, as well as additional experience with Parkview Physicians Group Psychiatry. At Viking, she serves as a key clinical point of contact for clients, helping with clinical questions, refills, prior authorizations, and direct support for our providers and care team.

For Nurses Week, our team shared notes of appreciation for Chris, and the words on her door say what we already know: she is calm, kind, steady, compassionate, and deeply appreciated.

In mental health care, the work is often complex, emotional, and demanding. Having someone like Chris on the team matters. She brings experience, patience, clinical judgment, and a quiet steadiness that helps both clients and staff feel supported.

Chris, thank you for the care you provide, the calm you bring, and the difference you make every day. Viking Psychiatry & Wellness is better because you are part of it.

Happy Nurses Week, Chris. You are appreciated.

04/30/2026

Today marks a meaningful advancement in neuropsychiatric care.

Axsome Therapeutics announced that the FDA has approved AUVELITY® (dextromethorphan HBr/bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer’s disease.

As someone who speaks on behalf of Axsome and has spent much of my career focused on glutamatergic modulation, NMDA receptor activity, and novel mechanisms in psychiatry, this approval is especially significant to me.

Agitation in Alzheimer’s disease is not simply “behavioral difficulty.” It can be one of the most distressing, dangerous, and caregiver-burdening aspects of dementia care. It affects patients, families, long-term care teams, and clinicians who are often left with limited options.

What stands out about this approval is the continued movement toward mechanism-based treatment in brain health. AUVELITY targets NMDA and sigma-1 receptors via its dextromethorphan component, and bupropion increases dextromethorphan exposure by inhibiting CYP2D6. This represents a distinct approach in an area of substantial unmet need.

This is also a reminder that neuroscience is evolving. Psychiatry and neuropsychiatry are no longer limited to older symptom-suppression frameworks alone. We are increasingly seeing treatments developed around circuits, neurotransmitter systems, neuroplasticity, and functional outcomes.

Congratulations to the Axsome team on this important milestone, and more importantly, to the patients, families, caregivers, and clinicians who may now have another FDA-approved option in a very difficult area of care.

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s...

03/19/2026

03/01/2026

So blessed to be looking at five years in business and having amazing people like this with us. Kayla Brumbaugh just hit her 3 year mark and is now the VP of Wellness. She cares passionately for our clients and the business. We must be doing something right to keep amazing folks like her. Blessed to have her here! Feel free to share some love for Kayla!

02/23/2026

Such an amazing woman and teacher. If you can assist would would be appreciated by her and the family. Large medical bills, and being out of work for some time.

Quick Status Update (At a Glance - 2/22/26): Zoë is currently… Maggie Lengacher needs your support for Support Zoë’s Recovery After Sudden Medical Emergency

02/17/2026

We are excited to announce that Viking Psychiatry will be exhibiting at Annual APRN Conference & Workshops on February 18 – 20, 2026. 🎉🎉 Like or comment if you’ll be there! - via Event Platform

01/26/2026

Viking Psychiatry & Wellness will be having a snow day Monday January 26th. All TMS, Ketamine, and Spravato will be cancelled/rescheduled. Appointments will be switched to telehealth. We don’t have these often but for the safety of staff and clients along with the road advisory’s, we feel it’s best to do so. Please stay safe and warm!

01/22/2026

At Viking Psychiatry & Wellness, we are intentionally pushing psychiatric care forward, reducing barriers, reducing burden, and expanding access to treatments that can truly change lives.

Neuro-Integrative Psychiatry is what we are bringing to the table.

Neuro-Integrative Psychiatry is a modern approach to mental health care that treats the brain, nervous system, and body as connected systems. In addition to medications and therapy, it uses advanced interventional treatments like ketamine, TMS, and esketamine, along with medical devices and hormone-based evaluations that address sleep, pain, sexual health, muscle function, and other physical drivers that impact mental well-being. The goal is not just symptom relief, but restoring brain-body balance so patients can function better overall.

We are proud to share that Viking Psychiatry & Wellness has been selected as a BTL Aesthetics Academic Center, making us the only psychiatric practice in the Midwest to hold this designation. This allows us to participate in advanced training, outcomes tracking, and clinical research, helping shape how these treatments are being used both now and in the future.

What does that mean for patients? Here is just ONE of the ways we are changing lives:

• A new treatment approach to TMS that can be completed in as few as 2 sessions per week for just 3 weeks, rather than daily treatments over 6–9 weeks
• Far less disruption to work, school, and family life
• A significant reduction in overall treatment burden
• A cost that is substantially lower than traditional TMS, which often totals $7,000–$12,000

Importantly, this care is not limited to severe or treatment-resistant depression. As psychiatry evolves, so does our understanding of who benefits from interventional brain-based treatments.

These therapies may support individuals seeking help with:
• Depression and anxiety
• Trauma-related symptoms
• PMDD and postpartum mood changes
• Brain fog, cognitive fatigue, and mental clarity
• Wellness-focused brain optimization and resilience

Our mission has been to make advanced psychiatric care more accessible, more efficient, and better aligned with real life, not reserved only for the most severe cases.

Please watch the attached video to learn more about how this treatment works and why it represents a meaningful shift in mental health care.

Viking Psychiatry & Wellness
Advancing care. Reducing burden. Expanding access.
https://www.instagram.com/reel/DSI_6zaDtYY/?utm_source=ig_web_copy_link